Cerevel Therapeutics Holdings, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. June 3, 2025 Deadline to file Lead Plaintiff Motion

Core Viewpoint - Cerevel Therapeutics Holdings, Inc. is facing a class action lawsuit from investors who purchased securities during the specified class period, alleging material omissions and misconduct related to a secondary stock offering and misleading statements regarding an acquisition by AbbVie [1][3]. Group 1: Class Action Details - The class action lawsuit seeks to recover losses for shareholders allegedly harmed by Cerevel's secondary stock offering on October 16, 2023, and false statements in the January 18, 2024 Proxy Statement regarding AbbVie's acquisition at $45 per share [3]. - The lawsuit claims that the October 2023 offering was orchestrated by Cerevel's controlling shareholders, Bain and Pfizer, to allow Bain to increase its stake at a discounted price before the undisclosed acquisition by AbbVie [3]. - Following the offering, Cerevel announced the acquisition by AbbVie for $45 per share, which was nearly double the offering price, resulting in a windfall of over $120 million for Bain [3]. Group 2: Investor Actions - Investors are encouraged to contact attorney Lesley F. Portnoy to discuss their legal rights and options for pursuing claims to recover losses [2]. - The deadline for investors to file a lead plaintiff motion is June 3, 2025 [1].